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ABSTRACT
The number of people with late-life schizophrenia is increasing, but few prospective longitudinal studies have analysed 
antipsychotic use in this group. The aim of this narrative review is to present key points of current knowledge regarding the use 
of antipsychotics in late-life schizophrenia. In general, antipsychotic medications have had a major impact on symptom relief 
in schizophrenia. If used with caution, they are relatively safe and effective in older patients. Given the significant somatic 
comorbidity and excess mortality in late-life schizophrenia, treatment approaches should include a combination of judicious use 
of antipsychotics with non-pharmacological treatments. Antipsychotics should be used cautiously with the goal of optimizing 
outcomes with regular monitoring of adverse effects and using lowest effective doses. Cessation of antipsychotic treatment may 
be possible for some patients.
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INTRODUCTION
An increasing number of people with schizophrenia will 
survive into advanced age following illness onset in early 
adulthood or midlife (1-4). Concordantly, the importance 
of geriatric psychopharmacology will increase. Scientific 
research on patients with schizophrenia largely focuses on 
patients diagnosed in early adulthood (EOS, early-onset 
schizophrenia), but patients with late onset (LOS, diagnosed 
at age 40-60) or very late onset (VLOS, diagnosed after age 
60 or more) of illness are also studied (5-6). In this review, 
individuals with late-life schizophrenia (over age 55-65) (1) 
are discussed regardless of the age of onset of illness. 
In late-life schizophrenia, as summarized by Cowling et 
al. 2012 (1), less frequent episodes of symptom exacerbation 
and increased sensitivity to medications are observed. Positive 
symptoms are less severe, negative ones may increase, 
substance abuse is less common and mental health functioning 
may improve. Hospitalizations are more likely to be due to 
physical problems rather than psychotic relapses. However, 
less is known about the real-world prescribing practices of 
psychiatrists for patients with late-life schizophrenia. Older 
age is a risk factor for antipsychotic side effects, including 
metabolic syndrome and movement disorders.
Data on the trajectory of schizophrenia in late life is 
essential for the planning of treatment and service provision. 
Due to changes in psychopathology and neuropathology, 
social functioning and physical health across the lifespan, 
we cannot assume that findings in younger patients apply to 
individuals with late-life schizophrenia.
Antipsychotics are efficacious during the acute and early 
maintenance phase of schizophrenia following acute illness 
episodes (7-11). Evidence on the efficacy of antipsychotics 
is less clear from a longitudinal or even lifespan perspective 
(9,12). Antipsychotics remain the mainstay of treatment for 
late-life schizophrenia. The effectiveness of both typical and 
atypical antipsychotics has been demonstrated, commonly 
favouring atypical antipsychotics (6). However, most of 
the evidence is not based on rigorously conducted trials. 
Effective non-pharmacological treatments have also yet to be 
developed.
We present here a narrative review of current knowledge 
of antipsychotic medication in late-life schizophrenia, 
particularly the clinical challenges, treatment algorithms 
and recommendations, medication management (7) and the 
efficacy of available antipsychotics. We also draw attention to 




In October 2019 we conducted a literature search in PubMed, 
Scopus, Web of Science and Cochrane Library using the 
following search terms (including MeSH): (aging OR ageing 
OR late life) AND schizophren* AND antipsychotic*. 
All identified studies were screened based on the title and 
abstract. Articles focusing on antipsychotic drug selection, 
dosing, discontinuation, adverse effects, risk-benefit ratio 
and clinical recommendations among patients with late-
life schizophrenia were included. Articles and books were 
also searched manually. The reference lists of both review 
and original research articles were examined to identify 
additional references that would be applicable to the goals 
of this paper. We considered a broad range of eligible 
approaches and study designs: observational studies (cross-
sectional, case-control, cohort or longitudinal, surveys, case 
studies, systematic reviews and meta-analyses) and also 
intervention studies.
NARRATIVE REVIEW
Narrative reviews highlight new and unanswered topics 
that are difficult to analyse in systematic reviews and tend 
to focus on author-selected studies (13). Our aim in this 
narrative review was, first of all, to analyse the existing 
literature on the key clinical questions of antipsychotics in 
late-life schizophrenia, primarily drug selection, dosing, 
discontinuation, adverse effects and the risk-benefit ratio. 
Finally, based on the literature and the authors’ own 
experiences, we present clinical recommendations for “real-
world” antipsychotic use in the Table.
3. RESULTS
SEARCH RESULTS AND SELECTED REVIEW TYPE
The search strategy identified potentially relevant articles in 
PubMed (n=220), Scopus (n=428), Web of Science (n=192) 
and Cochrane Library (n=38). After the removal of duplicates 
and non-relevant articles, 437 articles were selected for 
comprehensive evaluation. A total of 53 articles (listed in 
references) from the search and other sources were included 
in this narrative review. 
Only a few epidemiologically sound and representative 
studies and samples were found, as well as only a 
few systematic and updated treatment algorithms and 
recommendations. No randomized placebo-controlled trials 




schizophrenia. Many experts stressed that no guidelines can 
address the complexities of an individual patient at advanced 
age and sound clinical judgment based on clinical experience 
should be used. 
Existing data are difficult to analyse in a systematic 
quantitative review, and definitive treatment recommendations 
limited. Therefore, we performed a narrative review focusing 
on studies based on author selection (13). 
DRUG USE AND DOSING 
Among patients with late-life schizophrenia, the use of 
first-generation antipsychotics (FGAs) decreased, and the 
use of second-generation antipsychotics (SGAs) as well 
as combined and SGA use increased during 1998-2003 in 
Finland (6). Almost 40% of aged outpatients did not buy any 
antipsychotics (6).
Age effects on dosing of antipsychotics in schizophrenia 
have not been well understood. Age appears to have a biphasic, 
inverted U-shaped association with antipsychotic dose 
(14,15). The dose increases with age through the third decade, 
subsequently plateaus, and decreases after the fifth decade. 
Age-related decline in prescribed dose is likely associated 
with the natural history of schizophrenia and physiological 
ageing, suggesting that increased antipsychotic sensitivity 
with ageing comes from age-related functional decline in 
the dopaminergic system. This age-related antipsychotic 
sensitivity highlights the importance of finding the lowest 
possible effective dose of antipsychotics. In a study of 1,418 
patients across 30 sites in Tokyo, LOS and VLOS patients 
were treated with 1/2 and 1/3, respectively, of the dose for 
EOS (15). 
Lowest effective doses of antipsychotics are likely 
influenced by several clinical and demographic characteristics 
of patients, age being the most important. However, dosing 
and tolerability of antipsychotics have been studied primarily 
in younger patients, and very limited data are available for 
age-specific dosing. Due to the age-related physiologic 
changes as well as increased inter-individual variation in 
pharmacokinetics and pharmacodynamics, individualized 
dosing with regard to age will be important for safer drug 
treatment. Therefore, cautious psychopharmacologic 
interventions could include simple medication regimens 
avoiding polypharmacy, awareness of patients’ sensitivity to 
drugs, and gradual dose titration and regular monitoring.
Long-term antipsychotic medication, especially in high 
doses, has been repeatedly questioned (9). Current evidence-
based guidelines are undifferentiated (especially in mid- 
and long-term illness duration) in regard to optimal doses, 
dose tapering or low-dose maintenance therapy. Guidelines 
recommend low doses, but do not suggest how to go about 
tapering (i.e. at what point in the clinical course of illness, over 
what time period, etc.), as data on the safety of tapering is still 
limited, particularly for patients with late-life schizophrenia. 
Some studies have questioned whether patients with 
schizophrenia need to be on antipsychotics throughout their 
lives. Indeed, some adverse effects such as risk of tardive 
dyskinesia clearly associate with a total lifetime exposure to 
antipsychotics, especially FGAs. 
Strategies for personalized antipsychotic dosing and dose 
tapering may benefit a subgroup of patients (16), but may 
also be associated with incremental risk of relapse or excess 
mortality. When aiming for an optimal risk-benefit ratio and 
balancing symptomatic, functional and somatic outcomes, 
lower ranges of effective dosing are the primary goals. But 
what do the principles “lowest effective dose” or “according 
to individual patient needs” mean in clinical practice? 
Uchida et al. (17) found no differences between moderate 
antipsychotic dose (50-100% of the defined daily dose, 
DDD) and standard dose, with respect to overall treatment 
failure or hospitalization. Low dose (<50% of the DDD) were 
associated with greater risk of hospitalization and relapse. 
The current literature does not support the safe reduction of 
guideline-concordant antipsychotic dosing by 50% or more 
in stabilized individuals receiving originally moderate or high 
doses (9). Antipsychotic dose reduction is feasible in patients 
with stable disease, thus decreasing adverse effects (18).
Discontinuing antipsychotics. No guideline-concordant 
prescribing consensus exists on the optimal duration of 
antipsychotic treatment, especially among older patients, 
rather a tendency towards recommending continuous 
treatment in symptomatic patients (9). In studies with a long 
duration of follow-up, having first-episode psychosis (19) or 
midlife schizophrenia (20) about 30% and 20%, respectively, 
achieved remission with no use of antipsychotics. 
This literature search failed to find any studies in which 
antipsychotics were discontinued exclusively in patients with 
late-life schizophrenia and underscored a paucity of data. 
Discontinuation of antipsychotic treatment might be realistic 
in some patients with late-life schizophrenia, although more 
systematic studies are needed (21-23). Of course, many 
older patients with schizophrenia (almost 40% (6)) may self-
discontinue medication.
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ADVERSE EFFECTS AND CHALLENGES RELATED TO 
ANTIPSYCHOTICS IN LATE-LIFE SCHIZOPHRENIA
Clinical heterogeneity and wide inter-individual variations 
are hallmark features of late-life schizophrenia, with the 
course ranging from mild impairment to severe disability 
(1,24), also related to outcomes and side effects of 
antipsychotics. The varied course seen in younger patients 
with schizophrenia continues into later life, but remission 
and clinical and functional recovery are realistic goals for 
some individuals (1). 
A wide range of adverse effects related to antipsychotics 
are common and sometimes serious. There is little evidence 
of better efficacy of doses above the therapeutic range (25), 
and the general harm reduction strategy is to reduce to the 
lowest effective dose (26). Anticholinergics, benzodiazepines, 
antipsychotics and opioids all have significant adverse effects 
in the elderly population. In clinical practice, the most common 
side effects of antipsychotics include anticholinergic (such as 
urinary retention, constipation and confusion), neurologic 
(extrapyramidal symptoms, drug-induced parkinsonism and 
dyskinesia, tardive dyskinesia), altered thermoregulation, 
reduced bone density, metabolic syndrome, weight gain, 
increased visceral adiposity, (orthostatic) hypotension, 
poor dentition, excessive sedation and cardiac conduction 
disturbances. Both typical and atypical antipsychotics have 
been linked with an increased risk of falls and fractures in 
older patients (27). 
Polypharmacy, defined as being prescribed five or more 
medications, has been shown to be associated with a decline 
in mental and physical functioning in the elderly (28). Given 
the potential risks, careful monitoring of adverse effects and 
managing drug interactions are essential.
Antipsychotics and cognition. A high anticholinergic 
burden contributes to specific cognitive deficits. Older 
patients with schizophrenia experience relatively greater 
decline in cognitive functioning than other individuals (29) 
even though cognitive trajectories are heterogeneous. This has 
implications regarding their ability to function independently, 
and also regarding medication practices. High doses of 
antipsychotics may worsen cognition and reducing the dose 
may improve cognitive function (30).
Poor medication adherence is common in schizophrenia: 
about or over 50% in most studies. Antipsychotic non-
adherence (failing to initially fill or refill a prescription, 
discontinuing a medication before completing the therapy, 
taking more or less or other of a medication than prescribed) 
is an important risk factor for poor response and relapse 
(31). Many older patients have difficulty in remembering 
and understanding medication precepts of swallowing their 
tablets and capsules. Partial adherence to antipsychotic 
medication is a rule rather than exception in every age group 
with schizophrenia. 
Older people may be poor, socially isolated and 
suspicious or uncomfortable about medical interventions, and 
therefore actively avoid medications. Cognitive deficits may 
also hinder medication compliance, which, in turn, may lead 
to unintentional non-adherence. Illness denial and comorbid 
substance use may be important predictors of intentional non-
adherence (32). Side effects (e.g. sexual dysfunction, inability 
to drive) may lead to stopping the medication. Antipsychotic 
non-adherence is often underestimated by the treatment team 
and non-disclosure is common, as is also peer, relative and 
kinship support. 
Despite decades of focused research, unified approaches 
and practices that significantly increase adherence rates 
have not been identified (31). Improving adherence includes 
simplifying medication regimens, psychoeducation, engaging 
family support, (32) medication use of robots and other 
electronic interventions (33).
ANTIPSYCHOTICS AND SOMATIC COMORBIDITY
With ageing, positive symptoms of schizophrenia tend 
to become less severe and substance use less common, 
and mental health functioning may improve (1). Physical 
comorbidity is a rule, however, and older age is a risk factor 
for most side effects of antipsychotics, including metabolic 
syndrome and neurologic adverse effects (34).
Medical comorbidity is common throughout the life 
course of schizophrenia, but is particularly pertinent to older 
patients, given the increase in age-related disorders. The 
comorbid illnesses associated with premature death are often 
related to lifestyle factors such as smoking, diet and lack of 
exercise. These illnesses may also be exacerbated by certain 
treatments for schizophrenia. Antipsychotic medications have 
been responsible for a significant reduction in symptoms 
and mortality in a population-based patient sample with 
schizophrenia (35), but they can also cause negative effects, 
including impact on cardiovascular and metabolic function, 
diabetes and lipid levels. 
COMORBID DEPRESSION
Clinically significant depressive symptoms are common in 
older persons with schizophrenia (3) and can have a significant 
impact on quality of life, functioning, psychopathology and 
comorbid medical conditions. Most studies do not have 
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longitudinal data, therefore identification of the course of 
depression and the causal direction of associated variables is 
difficult to ascertain. It is important to systematically assess 
these individuals for symptoms of depression and actively 
utilize psychological and pharmacological treatments aimed 
at alleviating depressive symptoms.
The treatment of depressive symptoms in elderly patients 
with schizophrenia includes first reassessing the diagnosis to 
make sure that symptoms are not due to a comorbid condition, 
metabolic problems, substance abuse or medication. 
Augmentation with antidepressant medication can be helpful, 
and antidepressants in combination with psychosocial 
interventions are important treatments for older patients with 
schizophrenia and depressive symptoms (36). Some second-
generation antipsychotics may also relieve symptoms of 
depression (37).
ANTIPSYCHOTICS AND MORTALITY 
Reduced life expectancy (an average of 15-20 years) is a 
reality in schizophrenia (38). A register-based study by 
Talaslahti et al. 2012 (5) concluded that all-cause mortality of 
older patients with schizophrenia was almost three times that 
of the general population. Mortality from unnatural causes, 
such as suicides and accidents, was found to be eleven times 
higher than in the general population. Excess mortality may 
be the result of both lifestyle factors and lack of adequate 
medical care.
Prevention of excess mortality is an area of major concern 
in schizophrenia, regardless of age. Improving lifestyle, 
early diagnostics of medical comorbidity, adequate somatic 
and psychiatric care and suicide prevention are key targets 
in reducing mortality throughout the lifespan. Antipsychotic 
treatment may decrease all-cause mortality (35,39), but more 
studies are still needed in this age group.
MEDICATION MANAGEMENT IN OLD AGE 
SCHIZOPHRENIA
Medication management is an ongoing process to organize 
and monitor the recommended use of antipsychotics, aiming 
at the facilitation of their cost-effective, adherent, and 
acceptable use. Medication management is implemented 
by an optimal organizational environment, teamwork and 
therapeutic alliance (7). The age-related antipsychotic 
sensitivity and common somatic comorbidities highlight the 
importance of low doses to minimize side effects. Medication 
management may include multiple models and practices. For 
instance, Integrated Care Pathways (ICPs) are designed to 
manage specific conditions using standardized assessments 
and measurement-based interventions. Older patients with 
schizophrenia treated with antipsychotics within an ICP 
experienced higher rates of monitoring and less psychotropic 
polypharmacy than older patients treated with antipsychotics 
under treatment in usual conditions (40).
Skilled prescription practices or combining 
antipsychotics with psychosocial therapies and good 
medication management may improve their risk-benefit 
ratio. Key elements in medication management of patients 
with late-life schizophrenia are presented in the Table. These 
recommendations are based on the literature reviewed and 
clinical experiences of the authors. 
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Table: Key principles and practices in antipsychotic pharmacotherapy for elderly individuals  
with schizophrenia 
Patient perspectives
• Documenting illness and medication histories, clinical responses, informed consent for antipsychotics, 
efficacies, tolerance profile, safety, harms and side effects and their acceptability, adherence 
• Proper diagnosing of psychiatric and somatic disorders using medical examinations and routine 
laboratory studies 
• Assessing ageing pathways, cognitive function, insight into illness, drug experiences and attitudes, 
beliefs about antipsychotics and medication self-management skills  
• To maximize benefits and minimize harms favours simple regimens, avoidance of polypharmacy, 
awareness of patient sensitivity to drugs, gradual dose titration and finding the lowest effective dose
• When antipsychotics are started, titrated, switched (e.g. to clozapine or long-acting injectable 
antipsychotics), tapered or discontinued, a 1 to 3-month test period may help in weighing the risks and 
benefits
• Patient and family inclusion and home care in planning, decisions and adherence strategies
Prescriber and treatment team perspectives 
• Orientation to guidelines, reviews and meta-analyses aimed at appropriate prescribing patterns, drug 
choice and dose 
• Organizing optimal visit frequency and content
• Timely and thorough assessment of therapeutic response and side effects, risk-benefit ratio, duration, 
remission, recovery, cognitive capacities, somatic illness, non-adherence and treatment resistance 
• Monitoring for side effects and adverse effects in clinical and laboratory follow-up: most importantly 
sedation, tardive dyskinesia, extrapyramidal symptoms, metabolic disturbances, fall risk and cognitive 
impairment
• Recognizing and correcting inappropriate drug choices, doses and polypharmacy
• Team work useful especially in critical situations: early warning signs, relapse, antipsychotic treatment 
resistance, non-adherence, worsening tardive dyskinesia, somatic comorbidities, negative drug attitude, 
multiple prescribers and staff turnover or holidays
In summary
• In late-life schizophrenia the pharmacotherapy requirements change with ageing, comorbidities, 
symptom burden and illness phase
• Guideline-concordant algorithms are vague. No guidelines can address the complexities of an individual 
patient but personalized, tailored antipsychotic medication is needed 
• The critical aim rests on identifying the lowest effective dose of antipsychotics and optimizing benefits 
and harms
• Successful medication management rests on a participatory relationship, shared decision making, 
overcoming fragmentation, and having a general consensus between patients, relatives, other caregivers, 
clinicians and the treatment team 
• Combination of antipsychotics, psychoeducation, psychosocial interventions and somatic care should be 
offered to all individuals with late-life schizophrenia
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CURRENT TREATMENT RECOMMENDATIONS 
AND CLINICAL GUIDELINES FOR THE USE OF 
ANTIPSYCHOTICS IN LATE-LIFE SCHIZOPHRENIA
Treatment guidelines for older adults with schizophrenia 
consider the effects of age on the response to antipsychotics. 
Although atypical antipsychotics are used to treat very late-
onset schizophrenia-like psychosis, their benefits and risks 
have not been properly evaluated. No randomized placebo-
controlled trial data are available to guide antipsychotic 
treatment in late-life schizophrenia. Few clinical trials and 
case series in older adults (41) have demonstrated that the 
efficacy of antipsychotic medications may continue across 
the lifespan, rather that sensitivity to side effects in older 
age, with poorer tolerability may mitigate the benefits of 
treatment. 
Although antipsychotics play a key role in the treatment 
of older patients with schizophrenia, there has been a dearth of 
comparative data to guide selection of agents. Data on geriatric 
patients with schizophrenia are generally scarce, particularly 
for treatment-resistant subpopulations, underscoring the need 
for more research in this important area (42). Even in the most 
recent meta-analysis, the mean age of patients was 37 years, 
and despite the massive number of trials and patients (402 
RCTs, 53 463 participants) more data on the elderly patients 
are urgently needed (43). 
The ageing process has a substantial influence on the 
pharmacokinetics and pharmacodynamics of these treatments. 
Elderly patients are more sensitive to adverse effects and 
interactions, largely due to age-related changes in the 
central nervous system and the reduction of body’s capacity 
to metabolize antipsychotics and other drugs. As a result, 
recommended doses of many drugs (e.g. antipsychotics) are 
lower in the elderly. Starting doses of antipsychotic drugs 
in older patients should be in the range of 25-50% of that 
recommended for younger patients. Other challenging factors 
in this patient population include high rates of somatic 
comorbidity, drug interactions and age-related adverse effects 
to brain structure and functioning.
A 2012 Cochrane systematic review (44) of the 
use of antipsychotic medication for elderly people with 
schizophrenia was critical of the lack of robust data available 
to guide clinicians regarding the optimal administration 
of antipsychotics. The review states that there is no trial-
based evidence upon which to base guidelines for the 
treatment of late-life schizophrenia. There is a need for high 
quality randomized controlled clinical trials. Until they are 
undertaken, people with late-life schizophrenia will be 
treated by doctors using clinical judgement and habit to guide 
prescribing.
Among current first line options, SGAs have a better side 
effect profile and are more suitable for elderly people. Among 
SGAs, which are primarily used as long-term medication, 
the choice of medication should be guided by their clinical 
indications and adverse effect profile, with use of lower initial 
and target doses (compared to younger and midlife adults) 
and periodic reviews of whether or not their continued use is 
warranted (see Table). Based on one expert consensus (45), 
risperidone was recommended for use in first line treatment, 
with quetiapine, olanzapine and aripiprazole as second line 
agents. 
In treatment-resistant schizophrenia the gold standard 
is clozapine (24). Concerns about serious side effects have 
resulted in some avoidance of clozapine prescription for 
older patients. Common adverse effects include hypotension, 
weight gain, hypersalivation, constipation, sedation and 
myoclonus/seizure. Clozapine use is also associated with 
potentially fatal agranulocytosis (with modestly increased 
risk in elderly women) and myocarditis/cardiomyopathy. 
This perhaps also partly explains why almost all studies of 
clozapine to date have usually excluded older patients (46). 
Nevertheless, the benefits of clozapine use seen in seemingly 
intractable cases of schizophrenia in younger populations has 
encouraged researchers to re-examine its use in the elderly, 
particularly in cases where distressing psychotic symptoms 
are unresponsive to high doses of other antipsychotic 
medications. One study suggested that clozapine would be 
effective in reducing symptoms of schizophrenia in older 
patients (47). Where clozapine is used, dosing should be more 
cautious and regular monitoring (including therapeutic drug 
monitoring, at least when titrating clozapine dose) is required 
to ensure safety (48). 
Depot, i.e. long-acting injections (LAI), should be 
considered in older patients who have difficulties in taking 
medication because of their cognitive, psychological or 
physical impairments. The use of LAIs can help improve 
adherence to treatment (10,49).
5. DISCUSSION
MAIN RESULTS
In this narrative review, we present current knowledge of the 
clinical challenges, treatment practices and recommendations 
of antipsychotics in late-life schizophrenia. Treatment 
approaches should include a combination of judicious use of 
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antipsychotic medications with psychosocial treatments and 
medication management. Antipsychotic medications should 
be used at the lowest effective doses, and outcomes should 
be optimized by regular monitoring of both efficacy and 
adverse effects.
Few and methodically limited trials and observational 
studies in older individuals with schizophrenia have 
demonstrated that the efficacy of antipsychotics continues 
across the lifespan, rather that sensitivity to adverse effects 
increases in old age, which may mitigate their benefits. 
Antipsychotic drugs with a wider therapeutic spectrum and 
fewer side effects are urgently needed especially for older 
patients with schizophrenia.
UNANSWERED QUESTIONS AND DIRECTIONS FOR 
FUTURE RESEARCH
This narrative review revealed a paucity of literature or 
minimally studied topics related to antipsychotic medication 
in elderly patients with schizophrenia. The minimal 
availability of psychotherapy research in the area of late-
life schizophrenia is similarly troubling. Most results and 
recommendations (e.g. dosing) for schizophrenia are 
primarily based on younger patients with early or midlife 
onset of illness and thus may not apply to older adults.
Randomized controlled trials (RCTs) with long-term 
follow-up studies are difficult to conduct and tend to be 
rather reductionistic when analysing the complex, even 
lifespan interactions between the brain, environment and 
antipsychotics (12). 
Observational, naturalistic, non-experimental settings 
may be the only realistic option when investigating the long-
term effects of antipsychotics. However, in these studies the 
patients are not treated randomly which may cause residual 
confounding. Only a few studies present cumulative, long-
term or lifetime medication data.
Specific antipsychotic-related challenges among older 
individuals with schizophrenia are minimally studied, for 
instance, interactions between normal ageing, schizophrenia 
and antipsychotics, age-related changes in pharmacokinetics 
and pharmacodynamics and in the blood-brain barrier. Dose-
finding studies in elderly patients are rare even though mostly 
older patients are prescribed lower antipsychotic doses. The 
paucity of all these data makes optimal dosing challenging 
and highlights the importance of evaluation of adverse 
effects in elderly patients. Somatic comorbidities increase the 
number of prescribers and medications. The fragmentation 
in treatment increases the risk of suboptimal medication 
management (7). 
Ethical and legal issues provide guidance for medication 
management, especially the Hippocratic Oath: primum non 
nocere (first, do no harm): minimize or avoid the iatrogenic 
burden of antipsychotics (harmful adverse effects). The risk 
of long-term harms is the most important reason to minimize 
antipsychotic doses. In Finnish legislation on patient rights, 
the patient must accept their treatment (Finnish Act on the 
Status and Rights of Patients 1992), which in principle is 
especially pronounced in the treatment of schizophrenia.
Modern technology. Future challenges are to increase 
mHealth (i.e. mobile health) applications or electronic health 
and mobile devices, mainly wearable devices like mobile 
phones, to provide objective long-term data to monitor 
compliance, medication effects, symptoms or treatment 
progress. Information may range from skin conductance and 
temperature to the number of exchanged short message service 
(SMS) text messages to number of incoming and outgoing calls 
and electronic reminders. The variety of personal data, easily 
acquirable, offers a unique opportunity to study lifestyle and 
behaviour at the physical, cognitive and environmental level 
(50,51). These data may initiate a new trend in healthcare 
provision characterized by tailored interventions. It is still 
uncertain how older patients with schizophrenia and limited 
cognitive, economic and educational skills are able to adopt 
and use such modern technology and how these innovations 
effect the costs of care.
CONCLUSIONS 
An increasing number of people with schizophrenia 
survive into old age. The number of people with late-life 
schizophrenia spectrum disorders will increase in the coming 
years. There is still a paucity of scientific data regarding the 
developmental trajectory from illness onset in adolescence or 
early-mid adulthood into older age, even though interesting 
models (e.g. pathological accelerated ageing profile or even 
paradoxical ageing finding creative ways to age (52) well) 
are presented. However, longitudinal studies continue to 
defy the Kraepelinian notion of an inevitable deteriorating 
course of illness (53). Many older patients continue to have 
active disease, somatic comorbidity and high mortality, but 
some achieve sustained remission or recovery, and require 
minimal or no psychiatric care or medication. In contrast 
to early-onset schizophrenia, later onset of illness may also 
indicate enhanced social capital, longer occupational history 
and existing family and other social networks. 
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Schizophrenia remains a serious and debilitating disease 
for many older people, but studies continue to produce 
positive findings about our ability to alleviate symptoms, 
improve social and cognitive functioning and quality of life 
in this population. Antipsychotic medications have had a 
major impact on symptomatic relief and, if used with caution 
and skill, are relatively safe and effective in older patients. 
Recent studies support the need to develop rehabilitative 
interventions that enhance independent living skills, health 
and overall quality of life. Social integration, mood, cognition 
and physical health have critical roles in achieving successful 
ageing in schizophrenia. 
Still, many elderly patients with schizophrenia may have 
social disabilities making them vulnerable to poverty, isolation 
and poor quality of life, and therefore experiencing double 
stigmatization: one caused by schizophrenia itself, another 
by general ageism, perhaps as a reflection of ageist attitudes 
in wider society. Both are potential sources of prejudice and 
discriminatory practices. An improved understanding of 
the course of schizophrenia over the lifespan can advance 
our understanding when choosing the most appropriate 
antipsychotic medication in this complex disorder.
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